Kyntra Bio, Inc. (KYNB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Kyntra Bio, Inc. (KYNB) closed at USD 5.57 on 2026-10-14, a change of -48.5 % over the past year, with a market capitalization of USD 21.7M.

Kyntra Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Kyntra Bio, Inc. key figures

Previous close

USD 5.57 (2026-10-14)

1-year change

-48.5 %

Market cap

USD 21.7M

Enterprise value

USD -47.61M

P/E ratio (trailing)

-0.77

P/E ratio (forward)

-0.38

EPS (trailing)

-6.99

EPS (forward)

-14.23

PEG ratio

n/a

Price to book

-0.72

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.87

Employees

34

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Kyntra Bio, Inc.

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Kyntra Bio, Inc. and compare it with other stocks.